UCB (CHIX:UCBB) Momentum Rank : 6 (As of May. 11, 2024)

View and export this data going back to 2009. Start your Free Trial

What is UCB Momentum Rank?

UCB has the Momentum Rank of 6.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Competitive Comparison of UCB's Momentum Rank

For the Biotechnology subindustry, UCB's Momentum Rank, along with its competitors' market caps and Momentum Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

UCB's Momentum Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, UCB's Momentum Rank distribution charts can be found below:

* The bar in red indicates where UCB's Momentum Rank falls into.

UCB Momentum Rank Related Terms

Thank you for viewing the detailed overview of UCB's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

UCB (CHIX:UCBB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » UCB SA (CHIX:UCBb) » Definitions » Momentum Rank

Comparable Companies

Traded in Other Exchanges

UCBJY:USA UCBJF:USA 0NZT:UK UNC:Germany UCB:Belgium UCB:Austria

Address

Allee de la Recherche, 60, Brussels, BEL, B-1070

Website

https://www.ucb.com

UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), and Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome).

UCB (CHIX:UCBB) Headlines

No Headlines